Cancer research funding from the National Institutes of Health does not proportionally reflect which diseases are most deadly, according to a new study that examined federal investment across nine major tumor types in the United States. The findings raise pointed questions about whether current priorities align with clinical urgency or whether historical patterns and advocacy infrastructure are shaping resource allocation in ways that leave the most lethal conditions underserved.
The study analyzed 2025 NIH funding data alongside national incidence figures, five-year survival rates, and estimated mortality counts. Rather than relying on incidence alone, researchers used a metric that compares death rates to diagnosis rates to capture which types are most likely to kill the people they affect. The contrast between that measure and the funding each tumor type receives tells a striking story.
Where the money actually goes
Breast cancer received approximately 1.58 billion dollars in federal research funding, the highest of any disease examined. Prostate cancer received 662 million dollars and colorectal cancer received 494 million dollars. Those three diseases, all of which have seen significant survival improvements in recent decades, commanded a combined total that dwarfs what is allocated to conditions with far worse outcomes.
Pancreatic cancer has a mortality-to-incidence ratio above 0.85, meaning the vast majority of people diagnosed will die from it, yet it received just 440 million dollars. Small cell lung disease, which carries a similarly grim prognosis, received only 62 million dollars despite being among the most lethal diagnoses in oncology. Lung tumors collectively account for more than 150,000 estimated deaths annually, the highest of any type in the analysis, yet the funding they attract falls well short of what goes to more survivable conditions.
When funding is calculated per estimated death, the disparity becomes even more apparent. Prostate cancer received nearly 127,000 dollars per estimated death. Breast cancer received nearly 70,000 dollars per estimated death. Small cell lung disease received approximately 2,800 dollars per estimated death, a figure that reflects both its lower absolute funding and its devastating mortality toll.
What shapes the current funding landscape
Researchers identified several factors that help explain how these patterns developed. Diseases that have benefited from sustained philanthropic support, prominent advocacy movements, and early therapeutic breakthroughs have tended to attract and maintain higher levels of federal investment over time. That infrastructure reinforces itself: established research networks attract more dollars, which produces more results, which sustains the case for continued investment.
Conditions with limited advocacy presence or philanthropic backing depend more heavily on federal funding, which means that when federal priorities skew toward more survivable diseases, those with fewer outside champions are doubly disadvantaged. Industry investment, which often tracks incidence rather than lethality, can reinforce the same pattern, directing private research dollars toward larger patient populations rather than toward areas of greatest unmet need.
The case for a more balanced framework
The study’s authors called for a federal funding approach that incorporates incidence, survival rates, and mortality together rather than relying on any single measure. They also noted the importance of accounting for non-federal investment when evaluating where public dollars are most needed, since a disease that draws significant private and philanthropic support may warrant different federal prioritization than one that does not.
The researchers acknowledged limitations in their analysis, including the use of a single year of funding data and reliance on estimated rather than observed mortality figures. They also noted that funding decisions cannot be based on disease burden alone, as scientific opportunity, research feasibility, and prevention potential all factor into how resources are responsibly allocated. The study does not argue that better-funded diseases should lose support but that the most lethal ones deserve a more proportional share of what is available.
